Related Experiment Video

Updated: May 11, 2026

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
08:05

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

Therapeutic destruction of insulin receptor substrates for cancer treatment

Hadas Reuveni1, Efrat Flashner-Abramson, Lilach Steiner

  • 1NovoTyr Therapeutics Ltd., Israel; Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel. hadas.reuveni@gmail.com

Cancer Research
|May 9, 2013
PubMed

Insights

New agents targeting Insulin receptor substrates 1 and 2 (IRS1/2) eliminate these proteins, inhibiting cancer signaling. These IRS1/2 inhibitors show promise against drug-resistant melanoma and other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Insulin receptor substrates 1 and 2 (IRS1/2) are key mediators of signaling pathways crucial for cancer cell proliferation, survival, motility, and metastasis.
  • Upregulation of IRS1/2 is observed in various human malignancies and is linked to resistance against anticancer drugs, including B-RAF inhibitors.
  • Currently, no therapeutic agents specifically target IRS1/2 for cancer treatment.

Purpose of the Study:

  • To develop and evaluate novel agents targeting IGF-1R/IRS for cancer therapy.
  • To investigate the role of IRS1/2 in resistance to B-RAF inhibitors and assess the efficacy of IRS1/2-targeted agents in overcoming this resistance.
  • To demonstrate the preclinical proof-of-concept for IRS1/2 inhibitors as a therapeutic strategy in various cancers.

Main Methods:

  • Development of novel IGF-1R/IRS-targeted agents (NT compounds) designed to induce inhibitory Ser-phosphorylation and degradation of IRS1 and IRS2.
  • Assessment of NT compound efficacy in inhibiting IRS1/2-mediated signaling and inducing cancer cell death.
  • Evaluation of NT compounds in preclinical models of PLX4032-resistant melanoma, ovarian cancer, and prostate cancer, including in vivo studies.

Main Results:

  • NT compounds effectively promote IRS1/2 degradation, leading to long-term inhibition of IRS1/2-mediated signaling.
  • IRS1 upregulation was identified as a mechanism of resistance to B-RAF inhibitors in melanoma.
  • NT compounds eliminated IRS proteins in resistant melanoma cells, induced cell death, and demonstrated significant in vivo antitumor activity against resistant tumors and other cancers.

Conclusions:

  • The developed IRS1/2 inhibitors offer a novel therapeutic strategy for cancer, particularly for overcoming resistance to targeted therapies like B-RAF inhibitors.
  • Elimination of IRS proteins by these agents can prevent the acquisition of resistance to mutated B-RAF inhibitors and potentially restore sensitivity in resistant tumors.
  • These findings provide preclinical validation for IRS1/2 inhibitors as potent anticancer agents with broad applicability in various malignancies.

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...